DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol
Farmacia Hospitalaria · 2024
DOI: 10.1016/j.farma.2023.08.009 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Farmacia Hospitalaria, 2024. Verfasst von Sara Otero Torres und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Catalan Institut of Oncology - L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: saraotero@iconcologia.net. Hauptthemen laut MEDLINE: Fluorouracil, Antimetabolites, Antineoplastic, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION: The increased risk of severe and life-threatening toxicity in patients with dihydropyridine dehydrogenase (DPD) deficiency, under treatment with fluoropyrimidines, has been widely studied. An up-to-date overview of systematic reviews summarizing existing literature can add value by highlighting most relevant information and supports decision-making regarding treatment in DPD deficient patients. The main objective of this overview of systematic reviews is to identify published systematic reviews on the association between germline variations in the DPYD gene and fluoropyrimidine toxicity. METHODS AND ANALYSIS: This protocol was developed following the Preferred Reported Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) checklist, and the overview of systematic reviews will be reported in accordance with the PRISMA statement. PubMed, Embase, Scopus, and the Cochrane Library will be searched from inception to 2023. Systematic reviews irrespective of study designs that analyze the association between germline variations in the DPYD and fluoropyrimidine toxicity will be considered. Methodological quality will be assessed using AMSTAR2 checklist (Measurement Tool to Assess Systematic Reviews 2). Two independent investigators will perform the study selection, quality assessment, and data collection. Discrepancies will be solved by a third investigator. REGISTRATION DETAILS: Registration number in PROSPERO: CRD42023401226.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Catalan Institut of Oncology - L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: saraotero@iconcologia.net.
- Pharmacy Department, Catalan Institut of Oncology, Barcelona, Spain.
- Pharmacy Department, Catalan Institut of Oncology - L'Hospitalet de Llobregat, Barcelona, Spain.
Zitieren
APA
Torres, S. O., Pérez, O. M., Mauriz, R. R., Casamartina, E. F., Martínez, S. F., & Estela, A. C. (2024). DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2023.08.009
Vancouver
Torres SO, Pérez OM, Mauriz RR, Casamartina EF, Martínez SF, Estela AC. DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol. Farmacia Hospitalaria. 2024. doi:10.1016/j.farma.2023.08.009
BibTeX
@article{Torres2024,
author = {Torres, Sara Otero and Pérez, Olalla Montero and Mauriz, Rosa Rodríguez and Casamartina, Eduard Fort and Martínez, Sandra Fontanals and Estela, Ana Clopés},
title = {DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol},
journal = {Farmacia Hospitalaria},
year = {2024},
doi = {10.1016/j.farma.2023.08.009}
}
EUVIMED